Rajesh Krishnan | CTO
Oncternal Therapeutics

Festival of Biologics Day 1 @ 14:20

ONCT-808 autologous CAR T targeting ROR1 for patients with aggressive B cell lymphoma

Festival of Biologics Day 3 @ 10:05

T-Cell Therapy Vs T-Cell Engagers

A panel discussion to review and compare T-Cell Therapies (such as CART and TIL) with T-Cell Engagers (such as IL-2, anti-PD-1, bifunctional antibodies, and cancer vaccines)

Robert Dillman, CMO, AIVITA Biomedical, Inc.

×

Robert Dillman / T-Cell Therapy Vs T-Cell Engagers

Robert Dillman, Chief Medical Officer,
AIVITA Biomedical, Inc.

Dr. Robert O. Dillman, M.D., is Chief Medical Officer of AIVITA Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc. (formerly Neostem, Inc.), a leading development and manufacturing partner to the cell therapy industry. From May 2014 to January...

CloseMore

Rajesh Krishnan, CTO, Oncternal Therapeutics

Hans Keirstead, Chairman, Immunis Inc.

×

Hans Keirstead / T-Cell Therapy Vs T-Cell Engagers

Hans Keirstead, Chairman,
Immunis Inc.

Dr. Keirstead is an internationally renowned stem cell expert who has pioneered therapies for cancer, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. For over two decades, Dr. Keirstead has lead investigations on regenerative medicine. He spent 15-years as a...

CloseMore